Compare Infosys Limited (INFY) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Pfizer Inc — how do they compare? Infosys Limited trades at $10.73 (market cap $41.74B), while Pfizer Inc trades at $28.28 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 3.8× Infosys Limited's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Pfizer Inc for 158 Days on average.
| INFY | PFE | |
|---|---|---|
Market Cap | $41.74B | $158.56B |
Volume | 31,354,285 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $20.22 | $29.02 |
52-Week Low | $10.49 | $23.67 |
Typical Hold Time | 27 Days | 158 Days |
Enterprise Value | $39.48B | $210.06B |
Dividend Yield | 4.89% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.70, up 1.42% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong profitability with a 16.37% net income margin and ROE of 32.12%. Recent news highlights strategic AI collaborations with Columbia University and ABN Amro. Earnings history shows mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026.
The outlook is cautiously optimistic with a consensus price target of $11.48, offering potential upside. Risks include competitive pressures in IT services and volatile cash flow trends, with net cash flow turning negative in 2026. Analyst sentiment is mixed, with 35% buy ratings but 55% hold, reflecting uncertainty amid steady fundamentals.
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
